###begin article-title 0
###xml 44 47 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH</italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 98 108 98 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 509 514 <span type="species:ncbi:9606">human</span>
The human gene ERH (Enhancer of the Rudimentary gene Homologue) has previously been identified by in silico analysis of four million ESTs as a gene differentially expressed in breast cancer. The biological function of ERH protein has not been fully elucidated, however functions in cell cycle progression, pyrimidine metabolism a possible interaction with p21(Cip1/Waf1) via the Ciz1 zinc finger protein have been suggested. The aim of the present study was a systematic characterization of ERH expression in human breast cancer in order to evaluate possible clinical applications of this molecule.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 391 399 391 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 110 115 <span type="species:ncbi:9606">human</span>
The expression pattern of ERH was analyzed using multiple tissue northern blots (MTN) on a panel of 16 normal human tissues and two sets of malignant/normal breast and ovarian tissue samples. ERH expression was further analyzed in breast cancer and normal breast tissues and in tumorigenic as well as non-tumorigenic breast cancer cell lines, using quantitative RT-PCR and non-radioisotopic in situ hybridization (ISH).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 662 667 <span type="species:ncbi:9606">human</span>
Among normal human tissues, ERH expression was most abundant in testis, heart, ovary, prostate, and liver. In the two MTN sets of malignant/normal breast and ovarian tissue,ERH was clearly more abundantly expressed in all tumours than in normal tissue samples. Quantitative RT-PCR analyses showed that ERH expression was significantly more abundant in tumorigenic than in non-tumorigenic breast cancer cell lines (4.5-fold; p = 0.05, two-tailed Mann-Whitney U-test); the same trend was noted in a set of 25 primary invasive breast cancers and 16 normal breast tissue samples (2.5-fold; p = 0.1). These findings were further confirmed by non-radioisotopic ISH in human breast cancer and normal breast tissue.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 303 308 <span type="species:ncbi:9606">human</span>
###xml 486 491 <span type="species:ncbi:9606">human</span>
ERH expression is clearly up-regulated in malignant as compared with benign breast cells both in primary human breast cancer and in cell models of breast cancer. Since similar results were obtained for ovarian cancer, ERH overexpression may be implicated in the initiation and/or progression of certain human malignancies. Further studies on large breast cancer tissue cohorts should determine whether ERH could function as a prognostic factor or even a drug target in the treatment of human breast cancer.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 288 312 288 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster </italic>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 327 331 327 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 451 455 451 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 516 524 516 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 617 618 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 723 724 723 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 288 311 <span type="species:ncbi:7227">Drosophila melanogaster</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 593 598 <span type="species:ncbi:9606">human</span>
###xml 676 681 <span type="species:ncbi:9606">human</span>
The human ERH (Enhancer of the Rudimentary gene Homologue) gene encodes a protein highly conserved among eukaryotes. It has been identified after comparison of human ESTs with known genes in public databases, as a gene highly homologous to the enhancer of the rudimentary gene (DROER) in Drosophila melanogaster [1]. The human ERH consists of 797 nucleotides, including an open reading frame of 312 nucleotides, encoding a protein of 104 amino acids. ERH has been mapped to the chromosomal band 7q34 by fluorescence in situ hybridization, and its expression was originally found in all normal human tissues examined [1]. Details on the purification and crystallization of the human ERH protein have been reported recently [2].
###end p 11
###begin p 12
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">er(h) </italic>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DROER </italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XERH </italic>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 497 511 497 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus laevis</italic>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 610 626 610 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster </italic>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 842 852 842 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans</italic>
###xml 875 896 875 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arapidopsis thaliana </italic>
###xml 905 906 905 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 66 72 <span type="species:ncbi:9606">humans</span>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 329 334 <span type="species:ncbi:9606">human</span>
###xml 339 344 <span type="species:ncbi:10090">mouse</span>
###xml 497 511 <span type="species:ncbi:8355">Xenopus laevis</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 610 625 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 809 814 <span type="species:ncbi:9606">human</span>
###xml 842 852 <span type="species:ncbi:6239">C. elegans</span>
Intriguingly, the enhancer of the rudimentary gene - named ERH in humans, er(h) in all non-human species, DROER in Drosophila and XERH in Xenopus - is highly conserved among vertebrates, invertebrates, and plants with various orthologs identified, while there are no homologous sequences known within the same species [3-5]. The human and mouse coding regions are 93% identical, and the amino acid sequence of their proteins are completely identical to each other, as well as to that of the frog (Xenopus laevis) [3,4]. Furthermore, the human ERH protein has a 79.8% identity in amino acid sequence to that of D. melanogaster [1]. Similarly impressive is the conservation of hydrophobic amino acids: Of the 27 positions occupied by hydrophobic amino acids in DROER, 25 (93%) are conserved in the mosquito and human, 23 (85%) in the nematode (C. elegans), and 20 (74%) in the Arapidopsis thaliana protein [3].
###end p 12
###begin p 13
###xml 10 20 10 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 380 388 380 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 469 473 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 496 506 496 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 688 692 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 598 603 <span type="species:ncbi:9606">human</span>
###xml 756 761 <span type="species:ncbi:9606">human</span>
Using the in silico method electronic Northern (eNorthern) for RNA expression profiling, we have previously identified a genetic signature containing hundreds of candidate genes differentially expressed in breast and ovarian cancer [6]. Characterization of a subset of these candidate genes, by cDNA dot blot using cancer profiling arrays, real-time RT-PCR, non radioisotopic RNA in situ hybridization (ISH) and immunohistochemistry has been reported elsewhere [7-11]. ERH was identified by this in silico approach among other genes, and this gave us the impetus to further study its expression in human breast cancer. In the present study, we present a systematic expression analysis of ERH in a panel of breast cancer cell lines and malignant and normal human breast tissue samples using Northern blot, quantitative RT-PCR and non-radioisotopic RNA ISH.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Tissue Specimens and RNA extraction
###end title 15
###begin p 16
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 312 317 <span type="species:ncbi:9606">human</span>
Formalin-fixed paraffin-embedded tissue from breast cancer and corresponding normal tissue specimens were obtained from patients treated at the Gynaecology Department of the University Hospital of Aachen, with institutional review board approval. The cohort of breast tissue specimens analyzed in this study (25 human invasive breast cancers and 16 unmatched normal breast tissues) has been described previously [9]. The histopathological data of the tumours are summarized in Table 1. For each formalin-fixed paraffin-embedded tissue specimen six 4-mum thick tissue sections were cut with a microtome (Leica, Wetzlar, Germany) and transferred to a water bath filled with DEPC-treated water. Sections were mounted on standard glass slides, dried for 1 h at 60degreesC, and deparaffinized and rehydrated as follows: 2 x 15 min in xylole, 2 x 15 min in 100% ethanol, and short rinses in 96%, 70%, 50% ethanol followed by emersion in distilled water. Tissue material was transferred to a microcentrifuge tube and RNA was extracted according to the Trizol protocol supplied by the manufacturer (Life Technologies, Mannheim, Germany).
###end p 16
###begin p 17
Baseline characteristics of primary breast carcinomas (n = 25)
###end p 17
###begin p 18
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
a only female patients with primary, unilateral, invasive breast cancer were included
###end p 18
###begin p 19
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b according to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds.) Wiley, New York.
###end p 19
###begin p 20
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
c IRS: immune-reactivity score
###end p 20
###begin title 21
Cell lines and RNA extraction
###end title 21
###begin p 22
The non-tumorigenic breast cancer cell lines MCF12A and MCF10A, and five tumorigenic breast cancer cell lines (MCF7, SKBR3, T47D, ZR75-1, and BT-20) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured under recommended conditions. RNA from cell lines was extracted using the Trizol protocol (see above).
###end p 22
###begin title 23
###xml 65 70 <span type="species:ncbi:9606">human</span>
RNA expression analysis by northern blot in normal and malignant human tissues
###end title 23
###begin p 24
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 592 600 <span type="species:ncbi:9606">patients</span>
###xml 733 741 <span type="species:ncbi:9606">patients</span>
ERH expression was analyzed by multiple tissue northern blots (MTN) in a panel of 16 normal tissues, a set of four matched breast cancer/normal breast, and a set of four matched ovarian cancer/normal ovarian tissue samples (Clontech, Heidelberg, Germany). The following normal tissues were analyzed: heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. The breast cancer MTN contained four pairs of invasive ductal carcinoma and matched normal breast tissue from four female patients (51, 36, 47, and 45 years old). The ovarian cancer MTN contained four pairs of malignant and normal ovarian tissue from four female patients (age 48 - serous papillary cystadenocarcinoma; age 30 - papillary cystadenocarcinoma; age 42 - granulosa-theca cell tumour; age 28 - adenocarcinoma).
###end p 24
###begin p 25
###xml 59 61 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Hybridization was performed using 25 ng of a gene-specific 32P-labeled DNA probe derived from a Unigene cDNA clone [GenBank accession number ]. This gene-specific cDNA fragment was radiolabelled using a Megaprime labelling kit (Amersham Biosciences, Braunschweig, Germany), hybridized overnight at 68degreesC using ExpressHyb Hybridization Solution (Clontech, Heidelberg, Germany), washed, and exposed to Kodak XAR-5 X-ray film with an intensifying screen (Eastman Kodak Co, Rochester, NY).
###end p 25
###begin title 26
Quantitative RT-PCR
###end title 26
###begin p 27
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 53 57 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 241 252 239 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH mRNA </italic>
###xml 348 349 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 740 744 714 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
ERH mRNA-expression was analyzed with the LightCycler(R) system (Roche Diagnostics, Germany) in non-tumorigenic and tumorigenic breast cancer cell lines, and formalin-fixed paraffin-embedded breast cancer and normal breast tissue specimens. GAPDH mRNA was used as reference to obtain relative expression values. Primers used are presented in Table 2. Real-time RT-PCR was carried out with Fast Start DNA master hybridization probes (Roche Molecular Biochemicals, Germany). PCR conditions were as follows: initial denaturation in one cycle of 15 min at 95degreesC, followed by 40 cycles at 95degreesC for 20 sec, 60degreesC for 20 sec and 72degreesC for 30 sec. Reaction, data acquisition, and analysis were all done by using the LightCycler(R) instrument.
###end p 27
###begin p 28
Primers and probes used in real-time RT-PCR
###end p 28
###begin title 29
Non-radioisotopic RNA in situ hybridization
###end title 29
###begin p 30
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
Non-radioisotopic RNA ISH was performed as previously described [7,9]. In brief, riboprobes were obtained from plasmids containing cDNA inserts from the same clones used for array hybridization, linearized with restriction enzymes. Probes were digoxigenin-labeled using the Dig RNA labelling kit (Roche Applied Science, Mannheim, Germany). Paraffin embedded tissue specimens were deparaffinized, re-hydrated, washed two times in PBS, and processed according to the manufacturer's instructions (Roche Applied Science, Mannheim, Germany). Hybridized probes were detected using alkaline phosphatase conjugated anti-DIG antibodies and BM Purple as substrate (Roche Applied Science, Mannheim, Germany). After nuclear fast red counter staining (containing 5% aluminium sulphate; VWR International, Dublin, Ireland) sections were examined by a pathologist.
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
In order to compare the delta CT values of the real time RT-PCR results between specific groups the non-parametric Mann-Whitney-U-test was used.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Expression analysis using multiple tissue Northern blots
###end title 34
###begin p 35
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 229 233 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 85 90 <span type="species:ncbi:9606">human</span>
ERH expression was detected by multiple tissue Northern blots (MTN) in all 16 normal human tissues analyzed (Clontech, Heidelberg, Germany). ERH expression was most abundant in testis compared with other normal tissues. Abundant ERH expression was also found in normal tissue from the heart, ovary, prostate, and liver. Less abundant expression was detected in the remaining 11 normal tissues, with weakest expression in normal lung tissue. These results are presented in Figure 1.
###end p 35
###begin p 36
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ERH </italic>expression in human normal tissues analyzed by Northern blot hybridization</bold>
###xml 87 96 87 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH mRNA </italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 245 250 <span type="species:ncbi:9606">human</span>
ERH expression in human normal tissues analyzed by Northern blot hybridization. Strong ERH mRNA expression was found in normal testis, heart, ovary, prostate and liver. Less abundant ERH mRNA was detected in the remaining 11 tissues tested. The human ERH transcript is approximately 1.2 kb in size.
###end p 36
###begin p 37
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
ERH expression was further analyzed by MTN in a set of four matched breast cancer/normal breast tissue samples, and a set of four malignant/normal ovarian tissue samples (Clontech, Heidelberg, Germany). ERH expression was detectable in all malignant and normal breast tissue samples, and expression was clearly stronger in all tumour samples as compared with normal tissue samples (Figure 2, upper panel). The same expression pattern of more abundant expression in tumour compared with normal tissue samples was also seen in ovarian cancer (Figure 2, lower panel).
###end p 37
###begin p 38
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ERH </italic>expression in breast and ovarian cancer and normal tissue, analyzed by Northern blot</bold>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
ERH expression in breast and ovarian cancer and normal tissue, analyzed by Northern blot. ERH was expressed in all malignant and normal tissue samples. In both tumour entities, ERH expression was stronger in all tumour samples as compared with matched and non-matched normal tissue samples. Upper panel: breast cancer; lower panel: ovarian cancer. IDC: invasive ductal carcinoma; SPCA: serous papillary cystadenocarcinoma; PCA: papillary cystadenocarcinoma; GPCT: granulosa-theca cell tumour; AC: adenocarcinoma.
###end p 38
###begin title 39
Quantitative RT-PCR
###end title 39
###begin p 40
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 288 292 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 307 308 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 325 329 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 657 658 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
In order to investigate the possibility that ERH might be differentially expressed in different stages of mammary tumour progression we have compared ERH mRNA levels in non-tumorigenic (i.e. MCF10A and MCF12A cells) and five different tumorigenic breast cancer cell lines with LightCycler(R) RT-PCR (Figure 3). We found that ERH expression was significantly more abundant in tumorigenic cell lines as compared with non-tumorigenic cell lines (p = 0.05 according to two-tailed Mann-Whitney U-test). Interestingly, ERH was very abundantly expressed in the highly metastatic breast cancer cell line BT20. These results are presented diagrammatically in Figure 3.
###end p 40
###begin p 41
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ERH </italic>expression in benign and malignant breast cell lines. Diagrammatic presentation of quantitative RT-PCR data</bold>
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 175 180 <span type="species:ncbi:9606">human</span>
ERH expression in benign and malignant breast cell lines. Diagrammatic presentation of quantitative RT-PCR data. ERH expression was analyzed by real-time RT-PCR in the benign human breast cell lines MCF10A and MCF12A (grey columns) and in five breast cancer cell lines (black columns). ERH expression, normalized to MCF12A cells (set = 1.0), was significantly more abundant in breast cancer cell lines as compared with benign cell lines (p = 0.05).
###end p 41
###begin p 42
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 78 82 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 290 291 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 349 353 347 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 419 423 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
ERH expression was further validated by real-time RT-PCR using the LightCycler(R) system in a set of formalin-fixed paraffin-embedded tissue specimens, consisting of 25 primary invasive breast cancers and 16 normal breast tissue samples. These data are diagrammatically presented in Figure 4. Consistently with the MTN results presented above, mean ERH expression in breast tumours was 2.5 fold more abundant than mean ERH expression in normal breast tissue (p = 0.1 according to two-tailed Mann-Whitney U-test).
###end p 42
###begin p 43
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 0 107 0 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ERH </italic>expression in normal and malignant breast tissue. Diagrammatic presentation of quantitative RT-PCR data</bold>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
ERH expression in normal and malignant breast tissue. Diagrammatic presentation of quantitative RT-PCR data. ERH expression was analyzed by real-time RT-PCR in formalin-fixed paraffin-embedded tissue specimens. Mean ERH expression was 2.5-fold more abundant in breast tumours as compared to normal breast tissue (mean expression in normal breast was set = 1.0). N: normal breast; T: invasive breast cancer.
###end p 43
###begin title 44
Cellular localization of ERH mRNA
###end title 44
###begin p 45
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 297 298 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 425 429 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
Cellular localization of ERH mRNA in breast cancer and normal breast tissue was analyzed with non-radioactive RNA ISH. ERH expression was up-regulated in breast cancer as compared with normal breast tissue. Representative sections showing ERH expression as detected by ISH are presented in Figure 5. ERH was specifically and abundantly expressed in the tumour cells of invasive ductal carcinoma (D, G), while a less abundant ERH mRNA expression could be detected in the epithelial cells of normal breast lobuli (A).
###end p 45
###begin p 46
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 0 105 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative sections of <italic>ERH </italic>mRNA expression as detected by non-radioactive <italic>in situ </italic>hybridization (ISH)</bold>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
Representative sections of ERH mRNA expression as detected by non-radioactive in situ hybridization (ISH). A, D, and G: Hybridization with antisense ERH probe demonstrates ERH mRNA expression. B, E, and H: Hybridization with sense ERH probe serves as negative control for the specificity of the antisense probe. C, F, I: Hematoxylin-eosin staining of consecutive sections shown in ISH. ERH mRNA was clearly detectable in epithelial cells from invasive breast cancer (D, G), while a less abundant ERH mRNA expression could be detected in epithelial cells of normal breast tissue (A).
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 379 383 379 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 675 678 675 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH</italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 306 311 <span type="species:ncbi:9606">human</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 502 507 <span type="species:ncbi:9606">human</span>
###xml 777 782 <span type="species:ncbi:9606">human</span>
Thus far, a variety of different functions have been attributed to the ERH protein, including enhancement of pyrimidine biosynthesis, a role in cell cycle regulation, cell growth, repression of transcription and interaction with p21(Cip1/Waf1) [4,12-14]. Moreover, little is known about the role of ERH in human malignancies. In the present study, the gene expression pattern of ERH has been systematically analyzed in normal human tissues, breast cancer cell lines and a panel of malignant and normal human breast and ovarian tissue samples using three independent methods. Our analysis provides useful insights regarding the still inconsistently defined biological role of ERH. It is furthermore the first study to supply a systematic data set concerning ERH expression in a human malignancy.
###end p 48
###begin p 49
###xml 4 28 4 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Enhancer of rudimentary </italic>
###xml 57 80 57 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster</italic>
###xml 99 119 99 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rudimentary gene (r)</italic>
###xml 370 372 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r-</italic>
###xml 412 440 412 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Enhancer of the rudimentary </italic>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 706 710 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 865 869 865 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 936 937 936 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 57 80 <span type="species:ncbi:7227">Drosophila melanogaster</span>
The Enhancer of rudimentary gene was first discovered in Drosophila melanogaster: Mutations of the rudimentary gene (r), encoding a multifunctional protein for the first three enzymatic activities of the pyrimidine biosynthetic pathway, lead to a characteristic truncation of the wings. Mutation of another gene led to more severely truncated wings in the background of r-mutations, and thus this gene was named Enhancer of the rudimentary [5]. Later studies provided experimental evidence suggesting that the wild-type ERH protein is a transcriptional (co-)repressor [4,15,16] and its activity is not restricted to the pyrimidine biosynthetic pathway. Another hypothesis was based on the observation that ERH is only weakly expressed in non-dividing cell lines of hepatocytes while it is abundantly expressed in fibroblast and hepatoma cell lines, suggesting that ERH might have a function necessary for normal cellular proliferation [3].
###end p 49
###begin p 50
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 593 594 593 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
However, our findings do not support a key role of ERH in cellular proliferation, since ERH seems to be heterogeneously expressed in normal tissues expected to be transcriptionally active (more abundant expression in testis, ovary, prostate, and liver, but lower expression in placenta, kidney, pancreas, small intestine and colon - see Figure 1), as well as heterogeneously expressed in terminally differentiated tissues expected to have low transcriptional activity (very weak expression in lung, brain and peripheral blood leucocytes, but abundant in heart and skeletal muscle - see Figure 1).
###end p 50
###begin p 51
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 493 497 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 820 824 820 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 165 170 <span type="species:ncbi:9606">human</span>
Based on our finding that ERH is abundantly expressed in the majority of normal human tissues analyzed, it does not appear to be an ideal therapeutic drug target in human cancer treatment, but still such a role cannot be completely excluded. On the other hand, more abundant ERH expression in tumorigenic as compared with non-tumorigenic breast cancer cell lines (see Figure 3) and the trend of higher expression in malignant as compared with normal tissue samples (see Figure 4) suggest that ERH could be possibly used as a prognostic factor in breast cancer. Since similar results were obtained for ovarian cancer (see Figure 2), the expression pattern and the prognostic role of ERH in breast cancer and gynecologic malignancies awaits evaluation in future studies. Furthermore, this expression pattern suggests that ERH might be implicated in carcinogenesis and tumour-progression and this should be further investigated in appropriately designed functional studies.
###end p 51
###begin title 52
Conclusion
###end title 52
###begin p 53
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH </italic>
###xml 634 639 <span type="species:ncbi:9606">human</span>
###xml 846 851 <span type="species:ncbi:9606">human</span>
ERH expression is clearly up-regulated in tumorigenic as compared with non-tumorigenic breast cancer cell lines (found by quantitative RT-PCR), and in malignant as compared with normal breast tissue samples (confirmed by three independent methods, i.e. MTN, quantitative RT-PCR, and non-radioisotopic ISH). These findings suggest that ERH is progressively up-regulated with tumour progression, and thus it could be used as a prognostic factor in breast cancer. A similar expression pattern was also found in ovarian cancer (by MTN), suggesting that ERH overexpression might be implicated in the initiation and/or progression of other human malignancies as well. Further studies on large breast cancer tissue cohorts are necessary in order to investigate whether ERH could function as a prognostic factor or even a drug target in the treatment of human breast cancer, while functional studies should delineate its possible role in carcinogenesis and tumour-progression.
###end p 53
###begin title 54
Abbreviations
###end title 54
###begin p 55
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERH</italic>
###xml 49 61 49 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens</italic>
###xml 132 144 132 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens</italic>
###xml 347 356 347 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Situ H</italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 419 420 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 440 463 440 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster</italic>
###xml 49 61 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 132 144 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 440 463 <span type="species:ncbi:7227">Drosophila melanogaster</span>
ERH: Enhancer of the Rudimentary gene Homologue (Homo sapiens); erh: enhancer of the rudimentary gene homologue (species other than Homo sapiens); DROER: Drosophila Enhancer of Rudimentary; EST: Expressed Sequence Tag; MTN: Multiple Tissue Northern blot; RT-PCR: Reverse Transcription - Polymerase Chain Reaction; DEPC: Diethylpyrocarbonate; ISH: In Situ Hybridization; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; r: rudimentary gene (Drosophila melanogaster); XERH: Xenopus Enhancer of Rudimentary.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
The authors declare that they have no competing interests.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
MZ drafted the manuscript and participated in the design of the study and molecular studies. IL carried out the molecular studies. RK participated in the design and coordination of the study. ED conceived the study, performed the statistical analysis, and participated in its design and coordination, molecular studies, and drafting of the manuscript. All authors have read and approved the final manuscript.
###end p 59
###begin title 60
Pre-publication history
###end title 60
###begin p 61
The pre-publication history for this paper can be accessed here:
###end p 61
###begin p 62

###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
###xml 129 134 <span type="species:ncbi:9606">Human</span>
The study was supported by the German Ministry for Education and Research (BMBF grant 01KW0404 to E. Dahl) as part of the German Human Genome Project (DHGP).
###end p 64
###begin article-title 65
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 83 106 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Cloning and mapping of a novel human cDNA homologous to DROER, the enhancer of the Drosophila melanogaster rudimentary gene
###end article-title 65
###begin article-title 66
###xml 96 101 <span type="species:ncbi:9606">human</span>
Overexpression, purification, crystallization, and preliminary X-ray diffraction studies of the human transcription repressor ERH
###end article-title 66
###begin article-title 67
The putative cell cycle gene, enhancer of rudimentary, encodes a highly conserved protein found in plants and animals
###end article-title 67
###begin article-title 68
###xml 87 92 <span type="species:ncbi:9606">human</span>
ERH (enhancer of rudimentary homologue), a conserved factor identical between frog and human, is a transcriptional repressor
###end article-title 68
###begin article-title 69
Enhancer of rudimentaryp1, e(r)p1, a highly conserved enhancer of the rudimentary gene
###end article-title 69
###begin article-title 70
Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues
###end article-title 70
###begin article-title 71
Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer
###end article-title 71
###begin article-title 72
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumours
###end article-title 72
###begin article-title 73
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABRP </italic>
Systematic characterization of GABRP expression in sporadic breast cancer and normal breast tissue
###end article-title 73
###begin article-title 74
The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation
###end article-title 74
###begin article-title 75
###xml 44 53 44 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAI-RBP1 </italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERBP1</italic>
Expression analysis and RNA-localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumour progression
###end article-title 75
###begin article-title 76
Structure of the conserved transcriptional repressor enhancer of rudimentary homolog
###end article-title 76
###begin article-title 77
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human enhancer of rudimentary is a molecular partner of PDIP46/SKAR, a protein interacting with DNA polymerase delta and S6K1 and regulating cell growth
###end article-title 77
###begin article-title 78
###xml 115 120 <span type="species:ncbi:9606">human</span>
Ciz1, a p21 cip1/Waf1-interacting zinc finger protein and DNA replication factor, is a novel molecular partner for human enhancer of rudimentary homolog
###end article-title 78
###begin article-title 79
Methylation of SPT5 regulates its interaction with RNA polymerase II and transcriptional elongation properties
###end article-title 79
###begin article-title 80
Identification of proteins interacting with the RNAPII FCP1 phosphatase: FCP1 forms a complex with arginine methyltransferase PRMT5 and it is a substrate for PRMT5-mediated methylation
###end article-title 80

